DiaMedica Therapeutics Inc

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DiaMedica Therapeutics addresses FDA concerns amidst financial stability

DiaMedica Therapeutics maintains a strong financial position, but faces challenges with the clinical hold on their pivotal trial, requiring proactive resolution.
Despite increased expenses, the company's commitment to addressing regulatory feedback and ensuring patient safety presents growth opportunities in the long term.
Resolving the clinical hold swiftly and resuming trial enrollment are key priorities for DiaMedica to advance their clinical programs and unlock future potential.

DiaMedica progresses on FDA concerns with stable finances and new leadership

DiaMedica Therapeutics is actively addressing FDA concerns on DM199, supported by a stable financial position and a strengthened management team.
While facing challenges in meeting regulatory requirements and managing increased expenses, DiaMedica sees opportunities in resolving adverse events and advancing DM199.
Overall, DiaMedica's progress, financial stability, and strategic additions position the company well for potential FDA approval and further development of DM199.

DiaMedica Therapeutics reports strong Q2 performance and eyes global expansion

DiaMedica Therapeutics made significant progress in Q2 2023, achieving key milestones, strengthening financial position, and advancing product development.
While facing challenges in patient enrollment and legal matters, the company is well-positioned to capitalize on opportunities for global expansion and market growth.
Overall, DiaMedica's focus on efficient treatment delivery and commitment to innovation position them for future success in the biopharmaceutical industry.

DiaMedica reports solid Q3 results amidst strategic protocol enhancements

DiaMedica Therapeutics showcased robust financials in Q3 2023, driven by successful private placements and strategic cost management.
The appointment of Dr. Ambar Shah and protocol enhancements for ReMEDy2 reflect a commitment to innovation and clinical advancement.
However, challenges persist with patient enrollment, protocol adjustments, and legal proceedings, necessitating focused efforts to mitigate risks and drive progress.

DiaMedica Therapeutics reports robust 2023 performance and advances stroke treatment

DiaMedica Therapeutics' strong financial performance and progress in the ReMEDy2 trial highlight the company's growth potential.
Appointment of a new Chief Medical Officer and protocol revisions demonstrate a commitment to advancing clinical development efforts.
While facing challenges in site commitments and trial complexities, the company has opportunities for global expansion and market penetration.

DiaMedica reports robust Q1 earnings, eyes trial expansion opportunities

DiaMedica Therapeutics showcased strong financial performance and positive trial progress in Q1 2024.
While facing challenges such as increased operating expenses and a legal appeal, the company remains well-positioned for growth.
Opportunities lie in expanding trials, leveraging the success in China, and building a robust foundation for future drug development.

DiaMedica Therapeutics progresses on key programs amidst financial stability

DiaMedica Therapeutics is on track for a transformative 2025 with progress on key programs and enrollment enhancements.
Strategic protocol updates and financial stability bolster the company's position for future growth and clinical success.
Challenges around protocol changes and enrollment optimization require careful navigation for sustained progress.
Opportunities lie in protocol enhancements, regulatory milestones, and financial strength to drive innovation and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, has been invited to present at Lake Street’s 4th Annual Best Ideas Growth (BIG4) Conference, being held on Thursday, September 17, 2020, on a virtual platform.

DiaMedica Therapeutics to Present at Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for chronic kidney disease, today announced dosing of the first participants in the diabetic kidney disease (DKD) cohort of the REDUX Phase II Chronic Kidney Disease (CKD) study.

DiaMedica Announces First Patients Dosed in Diabetic Kidney Disease Cohort in Phase II REDUX CKD Clinical Study

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2020 Results - Earnings Call Transcript

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today provided a business update and financial results for the three and six months ended June 30, 2020.

DiaMedica Provides a Business Update and Second Quarter 2020 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the closing of its previously announced underwritten registered public offering of 4,600,000 of its common shares, including 600,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $5.00 per share, primarily with institutional investors including several specialist biotech funds and certain existin

DiaMedica Announces Closing of $23 Million Public Offering of Common Shares

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2020 financial results will be released after the markets close on Tuesday, August 11th.

DiaMedica Therapeutics to Report Second Quarter 2020 Financials and Provide a Business Update August 12, 2020

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of the previously announced underwritten registered public offering of 4,000,000 of its common shares at a price to the public of $5.00 per share.

DiaMedica Announces Pricing of $20 Million Public Offering of Common Shares

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today that it intends to offer and sell its common shares in an underwritten public offering.

DiaMedica Announces Proposed Public Offering of Common Shares

DiaMedica Therapeutics (NASDAQ: DMAC) shares are trading higher on Wednesday after Maxim Group initiated coverage on the stock with a Buy rating and announced a price target of $14 per share.

Why DiaMedica's Stock Is Trading Higher Today

DiaMedica Therapeutics Inc.'s (DMAC) CEO Rick Pauls on Q1 2020 Results - Earnings Call Transcript

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2019 Results - Earnings Call Transcript

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2019 Results - Earnings Call Transcript

MINNEAPOLIS, Sept.  06, 2019  (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will attend the Lake Street Capital Markets 3rd Annual Best Ideas Growth (BIG3) Conference on Thursday, September 12th, 2019, at the Parker New York in New York City.

DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019

MINNEAPOLIS, Sept.  03, 2019  (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor Conference in Minneapolis, Minnesota.

DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2019 Results - Earnings Call Transcript

Shares of the thinly traded nano-cap biotech DiaMedica Therapeutics Inc (NASDAQ: DMAC) were rallying strongly Thursday.

What's Pushing Nano-Cap Biotech DiaMedica's Shares Higher?

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2019 Results - Earnings Call Transcript

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2018 Results - Earnings Call Transcript

News for DiaMedica Therapeutics Inc Stock (DMAC)